Efficacy and Safety Profile of COVID-19 Vaccine in Cancer Patients: A Prospective, Multicenter Cohort Study

Ayşe İrem Yasin(Bezmiâlem Vakıf Üniversitesi), Sabin Göktaş Aydın(Istanbul Medipol University), Bilge Sümbül(Bezmiâlem Vakıf Üniversitesi), Lokman Koral(Canakkale Onsekiz Mart Universitesi Tip Fakultesi Hastanesi), Melih Şimşek(Bezmiâlem Vakıf Üniversitesi), Çağlayan Geredeli(Okmeydanı Eğitim ve Araştırma Hastanesi), Akın Öztürk(Yedikule Teaching Hospital), Perihan Perkin(Ankara Yıldırım Beyazıt University), Derya Demirtaş(Memorial Ankara Hospital), Engin Erdemoğlu, İlhan Hacıbekiroğlu(Sakarya University), Emre Çakır(Sakarya University), Eda Tanrıkulu(Haydarpaşa Numune Eğitim ve Araştırma Hastanesi), Ezgi Çoban(Haydarpaşa Numune Eğitim ve Araştırma Hastanesi), Melike Özçelik(Marmara University), Sinemis Çelik(Istanbul Eye Hospital), Fatih Teker(Gaziantep University), Asude Aksoy(Fırat University), Sedat Tarık Fırat(Erciyes University), Ömer Tekin(Inonu University), Ziya Kalkan(Dicle University), Orhan Türken(Maltepe University), Bala Başak Öven(Bahçeşehir University), Faysal Dane(Acıbadem University), Ahmet Bılıcı(Istanbul Medipol University), Abdurrahman Işıkdoğan(Dicle University), Mesut Şeker(Bezmiâlem Vakıf Üniversitesi), Hacı Mehmet Türk(Bezmiâlem Vakıf Üniversitesi), Mahmut Gümüş
Future Oncology
January 27, 2022
10.2217/fon-2021-1248
Cited by 31Open Access
Full Text

Abstract

Aim: To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 noncancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: NCT04771559 (ClinicalTrials.gov)

Related Papers

No related papers found

Powered by citation graph analysis